Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TERT | O14746 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2803987 | 0.89 | L3MBTL1 (0.53) | ALDH1A1LMNATERTMAPTTSHR | |
| SCHEMBL3938054 | 0.88 | ALDH1A1 (0.53) | ALDH1A1POLBKMT2ALMNATERT | |
| SCHEMBL2801775 | 0.88 | LMNA (0.54) | POLBKMT2ALMNATERTTSHR | |
| SCHEMBL955567 | 0.82 | ALDH1A1 (0.65) | ALDH1A1POLBKMT2ALMNATERT | |
| SCHEMBL3937668 | 0.78 | ATM (0.55) | ALDH1A1POLBLMNATERTGAA | |
| SCHEMBL2801161 | 0.78 | PGK1 (0.35) | ALDH1A1POLBLMNAGAA | |
| SCHEMBL2803444 | 0.74 | CDK2 (0.37) | ALDH1A1POLBLMNASMN1; SMN2 | |
| SCHEMBL15871949 | 0.73 | KDM4E (0.42) | ALDH1A1POLBKMT2ALMNAMAPT | |
| SCHEMBL3421270 | 0.72 | ALDH1A1 (0.56) | ALDH1A1POLBKMT2ALMNATERT | |
| SCHEMBL13934272 | 0.72 | ALDH1A1 (0.52) | ALDH1A1KMT2ALMNATERTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1845973-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2015-08-12 | — | — | EP | disclosed |
| US-9051278-B2 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators | ASTEX THERAPEUTICS, LTD. (GB) | 2015-06-09 | — | — | US | disclosed |
| EP-2256106-B1 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators | ASTEX THERAPEUTICS LTD (GB) | 2015-05-06 | — | — | EP | disclosed |
| US-20140371213-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS | ASTEX THERAPEUTICS, LTD. (GB) | 2014-12-18 | — | — | US | disclosed |
| US-8779147-B2 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators | ASTEX THERAPEUTICS, LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8404718-B2 | Combinations of pyrazole kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-26 | — | — | US | disclosed |
| US-20120213791-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS | ASTEX THERAPEUTICS, LTD. (GB) | 2012-08-23 | — | — | US | disclosed |
| US-8080666-B2 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators | ASTEX THERAPEUTICS, LTD. (GB) | 2011-12-20 | — | — | US | disclosed |
| EP-2256106-A1 | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators | Astex Therapeutics Limited (GB) | 2010-12-01 | — | — | EP | disclosed |
| US-7825140-B2 | Utilizing such as 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide against cancer growth | ASTEX THERAPEUTICS, LTD. (GB) | 2010-11-02 | — | — | US | disclosed |
| US-20080161355-A1 | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents | ASTEX THERAPEUTICS LIMITED (UK) | 2008-07-03 | — | — | US | disclosed |
| US-20080161251-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (UK) | 2008-07-03 | — | — | US | disclosed |
| WO-2008007122-A2 | COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008007113-A2 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| EP-1845974-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| EP-1845975-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| EP-1845973-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006077424-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077428-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077425-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161355-A1 | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents | ROS1, CDK9, GRK4 | ALDH1A1 3619/4885POLB 2626/4885KMT2A 1428/4885 |
| US-20120213791-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS | CDK3, CDK1, CDKL3 | ALDH1A1 3065/4885POLB 512/4885KMT2A 2473/4885 |
| US-20080161251-A1 | Pharmaceutical Compounds | HRH4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NR4A1 | ALDH1A1 3435/4885POLB 4212/4885KMT2A 2258/4885 |
| US-20140371213-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASE AND GLYCOGEN SYNTHASE KINASE-3 MODULATORS | CDK1, CDK3, CDK13 | ALDH1A1 3282/4885POLB 1170/4885KMT2A 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.